Persistent/Chronic Low Back Pain
Conditions
Keywords
pain, low back pain, GWAS, glycomics, activomics
Brief summary
Low back pain (LBP) is one of the most common medical problems encountered in daily life; it is related to disability and work absence and accounts for high economical costs in Western societies. Low-back pain is a diverse group of mixed pain syndromes (neuropathic and nociceptive) with different molecular pathologies at different structural levels displaying similar clinical manifestations. Currently, there are limited biomarkers (mostly imaging) or clinical findings that can be used objectively to help the physician in precise anatomic diagnosis leading to the safest and most cost-effective treatment for the patient (reduction of direct and indirect costs and improvement of treatment efficacy). The main aim of this trial is to identify all omics biomarkers associated with susceptibility to chronic/persistent LBP and its different pathophysiology.
Detailed description
Retrospective observational multinational clinical study, with a case control design. Investigators will compare omic biomarkers between patients with and without persistent chronic low back pain (CLBP). OMIC biomarkers investigated will be genetics, glycomics and activomic. Genetics through GWA studies has already obtained important results in pain research; however concerning low back pain, there is not yet suitable genotype-phenotype correlations helpful to stratify patients. Glycomics is an emerging field that has recently been identified as a priority for the next decade by the US National Academies of Science. Many common complex diseases will be associated with specific changes in glycan structures. In addition, common genetic polymorphisms influencing glycosylation and consequent differences in glycome composition could be important diagnostic and prognostic markers. The first studies reporting protein glycosylation in large human population samples have been recently published by partners in the consortium. Reliable identification of valid associations between specific glyco-phenotypes and predisposition for the development or progression of a specific disease requires analysis of thousands of patients. Activomics: combines data about enzymatic activity of numerous numerous post-translational modification proteins in an integrated model which provides dynamic characterization of the current state of an organism. In this project information about numerous proteases, kinases, phosphatases and glycosidases will be collected and used to complement the existing phenotype information.
Interventions
None listed
Sponsors
GENOS
Ip Research Consulting Sasu
Helmholtz Zentrum München
YURII AULCHENKO
King's College London
University of Parma
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
Yes
Inclusion criteria
of patients with persistent CLBP: * age: older than 18; * chronic/persistent pain (pain lasting longer than 12 weeks) between the costal margins and gluteal fold, with or without symptoms into one or both legs * written informed consent signed; * Caucasian ancestry Inclusion Criteria of healthy volunteers: * age: older than 18; * without any chronic/persistent pain (pain lasting longer than 12 weeks) in the last one year; * written informed consent signed; * Caucasian ancestry
Exclusion criteria
* evidence of clinically unstable disease; * severe psychiatric disorder (excluding mild depression) or mental impairment; * recent history ( \< 1 year) of spinal fracture; * pain in the back due to spinal tumor or infection; * pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| GENETIC OUTCOME | 30 months | The primary objective is to recognize genetic variants associated with persistent CLBP patients compared to patients without chronic/persistent pain. Through a Genetic Wide Association Study (GWAS) investigators will correlate genetic variants associated with persistent CLBP in a wide, international population of European ancestry. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| GLYCOMIC AND ACTIVOMIC OUTCOME | 30 months | Recognize Glycomic and Activomic data associated with persistent CLBP patients compared to patients without chronic/persistent pain. The sample size will better defined after the first interim analysis of first 400 patients. |
| STRATIFICATION OF OUR POPULATION | 30 months | All omic data will be compared stratifying our population according to: * Pathophysiology: discogenic pain, spinal stenosis, facet joint pain, sacroiliac joint pain, low back pain with radicular pain (not predominant radicular pain) and widespread pain. * pain intensity * response to treatment * duration of pain |
Countries
Australia, Belgium, Croatia, Italy, United States
Outcome results
None listed